Celltrion's bone disease biosimilars get approval in U.S.
SEOUL, Feb. 4 (Yonhap) - Celltrion Inc., a major South Korean biopharmaceutical firm, said Tuesday its two new biosimilars for bone disease treatment have obta...
Publicado el: 2025-03-04 05:44:06
Autor: yna.co.kr, Fuente: yna.co.kr
Compartir: 
